Gantanol

(Sulfamethoxazole)

ApprovedSmall molecule

CConrado Roberto Hoffmann Filho

Gantanol is one of 102 small molecule programs targeting Pneumonia. It is currently in Approved.

Indications

Total Trials

Active Trials

101

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

EndocarditisRecruiting

Acute BronchitisActive, not recruiting

ImmunodeficiencyActive, not recruiting

Type 1 DiabetesActive, not recruiting

PneumoniaPreclinical

Active, not recruiting

EndocarditisApproved

Recruiting

Acute BronchitisPreclinical

Active, not recruiting

ImmunodeficiencyPreclinical

Active, not recruiting

Type 1 DiabetesPhase 2

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Gantanol

CConrado Roberto Hoffmann Filho

Approved

2 2

Avlosulfon

AAlmirall, S.A.

Preclinical

4 3

Retrovir

BBp Consulting, Inc

Preclinical

2 4

Advil

KKenvue Brands

Preclinical

2 5

Zantac 150

CChattem

Preclinical

2 6

Pepcid

KKenvue Brands

Preclinical

1 7

Prograf

VVeloxis Pharmaceuticals

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Prilosec

DDexcel Pharma Technologies Ltd.

Preclinical

1 10

Mucinex

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Endocarditis

NCT05398679

Clinical

Trials by Indication[1]

Pneumonia2 trials

A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Completed·JJacobus Pharmaceutical·N/A·NCT00002283

Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia

Completed·UU.S. Bioscience·Phase 1·NCT00002120·20 enrolled

Type 1 Diabetes1 trial

Islet Transplantation for Type 1 Diabetes

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00014911·36 enrolled

Immunodeficiency1 trial

A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome

Completed·LLederle Laboratories·N/A·NCT00002002

Treatment1 trial

Sulfamethoxazole for the Treatment of Primary PREPL Deficiency

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 2·NCT02640443·15 enrolled

ALS1 trial

A Non-Interventional Safety Study of Balsamic Bactrim

Completed· Roche logo

Roche··NCT02902640·52 enrolled

2 more indications

Acute bronchitis1 trial

A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis

Completed· Roche logo

Roche··NCT02879981·51 enrolled

Endocarditis1 trial

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

Recruiting·FFundacion Clinic per a la Recerca Biomédica·Approved·NCT05398679·360 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

GANTANOL

NDA NDA013664

Jan 1, 1982

GANTANOL

NDA NDA012715

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Sulfamethoxazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sulfamethoxazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sulfamethoxazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA013664). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Conrado Roberto Hoffmann Filho company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CConrado Roberto Hoffmann Filho

Gantanol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pneumonia2 trials

Type 1 Diabetes1 trial

Immunodeficiency1 trial

Treatment1 trial

ALS1 trial

Acute bronchitis1 trial

Endocarditis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News